HC Wainwright Estimates Pelthos Therapeutics Q1 Earnings

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) – Analysts at HC Wainwright decreased their Q1 2026 EPS estimates for Pelthos Therapeutics in a research note issued to investors on Thursday, March 19th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($4.49) per share for the quarter, down from their previous forecast of ($1.88). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. HC Wainwright also issued estimates for Pelthos Therapeutics’ Q2 2026 earnings at ($3.48) EPS, Q3 2026 earnings at ($2.29) EPS, Q4 2026 earnings at ($2.60) EPS, FY2026 earnings at ($14.39) EPS, FY2027 earnings at ($1.51) EPS, FY2028 earnings at $10.86 EPS, FY2029 earnings at $15.42 EPS and FY2030 earnings at $18.79 EPS.

Several other brokerages also recently issued reports on PTHS. Oppenheimer increased their price target on Pelthos Therapeutics from $60.00 to $62.00 and gave the company an “outperform” rating in a report on Friday, March 20th. Zacks Research cut Pelthos Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, January 30th. Roth Mkm lowered their target price on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Finally, Piper Sandler assumed coverage on Pelthos Therapeutics in a report on Friday, February 27th. They set an “overweight” rating and a $48.00 target price on the stock. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $56.25.

Pelthos Therapeutics Stock Performance

NYSEAMERICAN:PTHS opened at $22.00 on Monday. The company’s fifty day simple moving average is $23.23. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.05 and a quick ratio of 1.15. Pelthos Therapeutics has a twelve month low of $9.00 and a twelve month high of $54.29. The firm has a market cap of $73.92 million, a price-to-earnings ratio of -1.06 and a beta of 3.87.

Institutional Investors Weigh In On Pelthos Therapeutics

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in Pelthos Therapeutics by 31.9% during the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after purchasing an additional 3,295 shares during the last quarter. Diadema Partners LP boosted its stake in shares of Pelthos Therapeutics by 138.1% during the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after buying an additional 14,502 shares during the last quarter. Cantor Fitzgerald L. P. acquired a new stake in shares of Pelthos Therapeutics during the fourth quarter worth approximately $1,085,000. J. Goldman & Co LP bought a new stake in shares of Pelthos Therapeutics in the fourth quarter worth $2,418,000. Finally, Ikarian Capital LLC increased its stake in shares of Pelthos Therapeutics by 309.5% in the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock worth $7,928,000 after buying an additional 193,307 shares during the last quarter. Institutional investors and hedge funds own 77.96% of the company’s stock.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).